Inclusion criteria:
  1. Patients with locally advanced or metastatic renal cell carcinoma
  2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor;
  3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time
  4. With first-line treatment carried out between 2007 and June 2016.
Exclusion criteria:
  1. Patient previously treated with only one cytokine (Interferon Î±2a, high-dose interleukin-2)
  2. Refusal of processing of personal data